Ozempic Vs. Glucose Monitors (feat. Sharam Fouladgar-Mercer) #685
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Ozempic Vs. Glucose Monitors (feat. Sharam Fouladgar-Mercer) #685” inside PodZeus.
In this episode of Biohacking News, host Tony Wrighton explores the growing debate around GLP-1 drugs like Ozempic and their long-term sustainability, citing a Cambridge University study showing people regain 60% of lost weight within a year of stopping the medication—often as fat rather than muscle. The episode contrasts this with the promise of Continuous Glucose Monitors (CGMs), particularly Cignos, co-founded by Sharam Fouladgar-Mercer, who shares his personal journey from obesity to using CGM data to achieve lasting metabolic health. Fouladgar-Mercer argues that while GLP-1s are powerful tools, they don’t teach behavior change—making them incomplete without a system like Cignos that provides real-time, personalized feedback to optimize diet, sleep, stress, and movement. The discussion also addresses skepticism from Johns Hopkins about CGM utility in non-diabetics, countered by Cignos’ large-scale clinical trial data and FDA clearance. The episode concludes with a call to action for listeners to consider CGMs not just as weight loss tools, but as lifelong metabolic coaches.
GLP-1 drugs lead to significant weight loss but 60% of weight is typically regained within a year, often as fat, not muscle.
CGMs provide real-time, personalized metabolic feedback that helps users understand how food, sleep, stress, and timing affect glucose and weight.
Sustainable weight management requires behavior change, not just medication—CGMs act as a 'wrapper' to teach lasting metabolic habits.
The effectiveness of CGMs is not just about data—it's about actionable insights and guided behavior change.
Cignos’ FDA-cleared platform combines CGM technology with behavioral science to help users maintain weight loss long-term.
…and 3 more takeaways available in PodZeus
The Weight Regain Crisis After GLP-1 Drugs
“People regain, on average, 60% of their lost weight within a year of stopping GLP-1 drugs. And the regained weight may be disproportionately fat rather than muscle, potentially leaving people worse off than before they started.”
Introducing Sharam Fouladgar-Mercer and Cignos
Tony introduces Sharam Fouladgar-Mercer, a former obese athlete who co-founded Cignos, the first FDA-cleared glucose monitoring system for weight management, sharing his personal story of metabolic struggles and the birth of the company.
Why Traditional Dieting Fails: The Metabolic Reality
“If you eat something after having slept for nine hours last night, your body's going to process it differently than if you slept for one or two hours last night.”
Cignos as the 'Exit Plan' for GLP-1 Users
“The key is not whether GLP-1s are great or terrible. GLP-1s are a really powerful tool, but it's how do you wrap that in a solution that ensures you can maintain that level of success when you ultimately want to get off that?”
The Science Behind CGM and Behavior Change
Cignos combines FDA-cleared CGM tech with behavioral science to create actionable insights—like meal timing, eating speed, and pre-bed eating—proven to reduce glucose spikes and support sustainable habits.
“People regain, on average, 60% of their lost weight within a year of stopping GLP-1 drugs. And the regained weight may be disproportionately fat rather than muscle, potentially leaving people worse off than before they started.”
“The key is not whether GLP-1s are great or terrible. GLP-1s are a really powerful tool, but it's how do you wrap that in a solution that ensures you can maintain that level of success when you ultimately want to get off that?”
“If you eat something after having slept for nine hours last night, your body's going to process it differently than if you slept for one or two hours last night.”
Host
Guest
Cignos
organization
Tony Wrighton
person
Sharam Fouladgar-Mercer
person
GLP-1 Drugs
product
Ozempic
product
FDA
organization
Johns Hopkins
organization
Keto Diet
other
Cambridge University
organization
Oura Ring
product
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Ozempic Vs. Glucose Monitors (feat. Sharam Fouladgar-Mercer) #685” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime